Gene therapy study for young boys with XLMTM on ventilators
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system clinical trials.
This study tests a new gene therapy called ASP2957 in young boys with X-linked myotubular myopathy who are dependent on a ventilator. The goal is to see if it can help improve their breathing and muscle strength.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be 36 months old or younger at the time of treatment.
- Your child must need a ventilator (breathing machine) for at least 20 hours a day and have a tracheostomy tube.
- Your child must have a confirmed genetic diagnosis of X-linked myotubular myopathy (XLMTM).
- Your child must be up to date on recommended vaccinations (or have a medical reason for missing any).
- Your child must not have certain infections (like active hepatitis, HIV, or COVID-19) or serious liver problems.
- Your child must not have received other gene therapy or certain immune-suppressing medications before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the liver works in boys with a serious muscle condition called XLMTM. It checks whether their liver is healthy, which may help doctors better understand the condition and guide future treatments.
This study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy. The goal is to see if it is safe and can help improve muscle function. It is for boys aged 4 to 8 who can still walk.
This trial tests a new cell-based treatment for Duchenne muscular dystrophy in adults who can no longer walk. The goal is to see if the therapy can help improve muscle function.
This trial tests a one-time gene therapy (SAR446268) for people with non-congenital myotonic dystrophy type 1. It aims to see if the treatment is safe and can improve muscle symptoms like stiffness and weakness.
This study tests a one-time gene therapy given by injection into the spinal fluid (intrathecal) for boys with Duchenne muscular dystrophy. It aims to see if the treatment is safe and how it spreads in the body, and may offer a new way to slow the disease.
This trial tests a gene therapy called GNR-097 for boys with Duchenne muscular dystrophy (DMD). The therapy aims to help improve muscle function, and the study will check how safe and effective it is.
Hear when a new X-Linked Myotubular Myopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.